These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34354581)

  • 1. Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials.
    Kong F; Wang J; Zheng H; Cai H; Hua J; Li L
    Front Pharmacol; 2021; 12():652759. PubMed ID: 34354581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials.
    Xu X; Xie L; Wei L; Li M; Wang H; Zhou H; Sun M; Yang M; Xu Q; Yang K; Wei S
    Adv Ophthalmol Pract Res; 2022; 2(3):100064. PubMed ID: 37846287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis.
    Aungsumart S; Youngkong S; Dejthevaporn C; Chaikledkaew U; Thadanipon K; Tansawet A; Khieukhajee J; Attia J; McKay GJ; Thakkinstian A
    Front Neurol; 2023; 14():1166490. PubMed ID: 37082442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials.
    Xue T; Yu J; Chen S; Wang Z; Yang Y; Chen Z; Wang Z
    Front Neurol; 2020; 11():604445. PubMed ID: 33391166
    [No Abstract]   [Full Text] [Related]  

  • 9. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
    Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
    Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.
    Xie Q; Zheng T; Sun M; Sun J; Wang M
    Mult Scler Relat Disord; 2020 Oct; 45():102421. PubMed ID: 32731203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
    Dong GY; Meng YH; Xiao XJ
    Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.
    Uzunköprü C; Tütüncü M; Gündüz T; Gümüş H; Şen S; Demir S; Çınar BP; Türe HS; Uygunoğlu U; Toğrol RE; Terzi M; Kürtüncü M; Özakbaş S; Tütüncü M; Beckmann Y; Siva A
    Int J Clin Pract; 2021 Jul; 75(7):e14158. PubMed ID: 33743552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.